Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed.

  • Q1 net sales declined -2% (cc¹, +1% USD), due to prior year COVID-19 related forward purchasing (approximately USD 0.4 billion)
    • Pharmaceuticals BU in line with prior year (0% cc, +4% USD) with continued strong growth from Entresto (+34% cc), Zolgensma (+81% cc), and Cosentyx (+11% cc). Kesimpta sales reached USD 50 million
    • Oncology BU grew +1% (cc, +4% USD) driven by Kymriah (+55% cc), Promacta/Revolade (+13% cc), Kisqali (+19% cc) and Jakavi (+8% cc). …
/by

Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed.

  • Q1 net sales declined -2% (cc¹, +1% USD), due to prior year COVID-19 related forward purchasing (approximately USD 0.4 billion)
    • Pharmaceuticals BU in line with prior year (0% cc, +4% USD) with continued strong growth from Entresto (+34% cc), Zolgensma (+81% cc), and Cosentyx (+11% cc). Kesimpta sales reached USD 50 million
    • Oncology BU grew +1% (cc, +4% USD) driven by Kymriah (+55% cc), Promacta/Revolade (+13% cc), Kisqali (+19% cc) and Jakavi (+8% cc …
/by

World Malaria Day 2021

The COVID-19 pandemic highlights the importance of robust health systems to respond to disease outbreaks and to control other deadly diseases such as malaria. On World Malaria Day, April 25, we are calling on the global health community to continue to uphold progress and commitments made in the fight to end malaria.

Follow us on social media at #MalariaFuture

…

/by

Novartis to initiate SMART Phase 3b global study of Zolgensma in children up to 21 kg, building on real-world experience

  • SMART study to extend data beyond patient population studied in clinical trials
     
  • New clinical study to evaluate safety and efficacy of Zolgensma in children up to 21 kg, adding to real-world experience and regulatory approvals in Europe and Canada

Basel, April 23, 2021 — Novartis today announced plans to initiate SMART, a Phase 3b clinical study to evaluate the safety and efficacy of Zolgensma® (onasemnogene abeparvovec) in young children with spinal muscular atrophy (SMA) weighing ≥ 8.5 kg and ≤ 21 kg …

/by

Kesimpta® (ofatumumab) data at AAN showed reduction in disability progression independent of relapse activity in newly diagnosed patients with RMS

  • Kesimpta reduced the risk of disability progression independent of relapse activity (PIRA) by up to almost 60% vs first-line teriflunomide in a subgroup of newly diagnosed, treatment-naïve patients with relapsing forms of multiple sclerosis (RMS) according to new post hoc data from the Phase III ASCLEPIOS trials, further supporting Kesimpta as a first-choice treatment option for adults with RMS1

  • More than 50% of confirmed disability worsening events in newly diagnosed, treatment-naïve RMS patients were PIRA, an emerging endpoint …
/by

Novartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche’s Actemra/RoActemra®

  • Initial agreement covers reservation of the large-scale state-of-the-art biologics facility in Singapore site for the production of the active pharmaceutical ingredient for Roche’s Actemra/RoActemra®
  • Follows recent initial agreements for providing manufacturing capacity for CureVac and BioNtech   

Basel, April 15, 2021 — Novartis has signed an initial agreement with Roche to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient (API) for Roche’s …

/by

World Chagas Disease Day 2021

Today is World Chagas Disease Day. This celebration, the second in history, takes place against the backdrop of the COVID-19 pandemic which continues to disproportionately affect vulnerable populations around the world, including people affected by Chagas disease. Patients who have heart conditions caused by Chagas disease could be at higher risk of severe complications from COVID-19.

Considered by the World Health Organization as one of the 10 neglected tropical diseases, Chagas disease affects approximately 6 million people, mainly in Latin America – yet it has spread in recent …

/by

Bringing Chagas disease to people’s attention

Chagas disease affects approximately six million people, mainly in Latin America. The disease can be silent for decades until it may become fatal, leading to cardiovascular complications in up to 30% of patients. Like other neglected tropical diseases, Chagas disease often affects poor and marginalized communities.

For the second time in history, the global community officially celebrated World Chagas Disease Day in April 2021 to bring the disease to people’s attention. Discover the stories of people affected by Chagas disease.

Photographer Ana Ferreira travelled to Bolivia, …

/by

Novartis receives EU approval for Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis

  • There are more than 1 million people living with multiple sclerosis (MS) in Europe1, Kesimpta® (ofatumumab) addresses the current unmet need for a high-efficacy disease-modifying therapy (DMT) that combines powerful efficacy and favorable safety profile with the flexibility of self-administration at home via the Sensoready® autoinjector pen2,3
  • Approval based on two Phase III ASCLEPIOS studies that met primary endpoints where …
/by

Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)

  • Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialize therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74

  • Broad expression of FAP demonstrated in tumors or in tumor stroma across many solid tumors1,2,3

  • Novartis Oncology continues to reimagine cancer care through development of robust radioligand therapy portfolio

Basel, March 30, 2021 — …

/by